Dr Martin Edwards is Senior Partner at Novo A/S, which he joined in 2003. He is chairman of the Board of Directors of NeRRe Therapeutics Ltd., and a member of the Board of Directors of KalVista Pharmaceuticals Ltd, Karus Therapeutics Ltd, Epsilon-3 Bio Ltd, Funxional Therapeutics Ltd and Tarsa Therapeutics Inc. He also holds an adjunct professorship at Copenhagen Business School (CBS SIMI).
From 1998-2003, Martin was the CEO of ReNeuron Holdings, taking that company public in 2000 and raising a total of £25m in equity and debt financing. From 1994-1998, he was Corporate VP and Head of Drug Development for Novo Nordisk A/S where he was responsible for all aspects of preclinical and clinical drug development. Previously, Martin worked for six years in the USA first as VP Pharmacology and Medical Affairs of ZymoGenetics Inc. in Seattle, and then as Senior VP for Medical Affairs at Novo Nordisk in Princeton NJ.
Martin trained in physiology and medicine in Manchester. He is a Member of the Royal Colleges of Physicians, a Member with distinction of the Royal College of General Practitioners, a Fellow of the Faculty of Pharmaceutical Medicine and holds an MBA from the University of Warwick.
Andrew Crockett, Director
Andrew Crockett is a Director of Vantia Ltd. He joined Vantia in 2009 from the US specialty pharma company ZARS Pharma where he was most recently VP Business Development. He is also co-founder, CEO and Director of KalVista Pharmaceuticals.
During his career Andy has identified, negotiated and executed strategic corporate transactions on a global basis, including merger and acquisitions, national and international product licences, IP and technology licences, and R&D alliances.
Andrew studied at Harvard Business School and also holds an MBA from The Wharton School, University of Pennsylvania, with a major in Finance.
Chris Yea, Co-Founder
Chris is a co-founder of Vantia Ltd. Chris holds a BSc and PhD in Biochemistry from the University of Bristol, UK. He has spent over 25 years in the industry starting his pharmaceutical career at Roussel-UCLAF in various research roles. In 1997 he joined Ferring Pharmaceuticals and led the project which delivered fedovapagon as a clinical candidate.
Chris co-led the spin-out of Ferring’s research unit raising venture funding to form Vantia Ltd in 2008 where he was responsible for the clinical development of fedovapagon. Chris was Chief Operating Officer of Vantia until 2015.
Chris is currently Chief Development Officer of Kalvista Pharmaceuticals Ltd.
Stephen Donnelly, CFO
Stephen has over fifteen years of experience working with healthcare companies. He holds professional accounting
and company secretarial qualifications and previous positions in the industry include Chief Accountant/Company
Secretary for Anagen PLC, a diagnostic company quoted on the LSE, and CFO/Company Secretary of Alfa Biotech (UK)
Limited, a UK subsidiary of an Italian pharmaceutical company. Stephen has also had a senior management role with
other venture capital healthcare companies including Novarticulate Holdings Ltd and Rodaris Pharmaceuticals Ltd.
In addition to these roles in the healthcare industry he also held the position of Director of Finance and
Administration for the London Office of The Nasdaq Stock Market Inc.
Rachel Morten, Head of Regulatory Affairs
Rachel has worked in global regulatory affairs and product development for over 25 years. She founded ChapelPharma,
a regulatory consultancy that was acquired by Hesperion (now Averion International Ltd) in 2004.
Now an independent regulatory affairs consultant, Rachel has worked with Vantia since 2009. She was made a Fellow
of TOPRA in 2012.
Rachel Handy, Clinical Development
Rachel holds a BSc and PhD in Pharmacology from the University of London. She has worked in Pharmaceutical Research
and Development for 20 years, previously working for Merck, Sharpe & Dohme, Astra, Cambridge Antibody Technology and
Ferring. She has extensive experience in the areas of women’s health and urology and has led projects from discovery
through to pivotal clinical trials. Rachel now manages the clinical operations for all Vantia programs.
Michael Roe, CMC
Michael graduated form the University of Cambridge in 1987, obtained a PhD from the University of Salford in 1994 and
carried out post-doctoral studies at the University of Texas, Austin, USA. Michael has previously worked at Merck,
Xenova and Ferring where he held the position of Head of Medicinal Chemistry. He has worked at Vantia since it was
founded in 2008 and is responsible for CMC at Vantia as well as for Vantia’s IP portfolio.